Skip to main content

Table 2 The outcome of subgroup analysis stratified by platinum regimen and ethnicity

From: Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis

Subgroups

Pooled HR

95%CI

P-Value

I2 For Homogeneity

Total

Cisplatin

0.87

0.80–0.95

0.002

28%

HR = 0.85, 95%CI 0.78–0.92, P<0.0001, I2 = 27%

carboplatin

0.72

0.58–0.89

0.002

0%

Asian people

0.80

0.69–0.94

0.005

50%

non-Asian people

0.86

0.79–0.95

0.003

20%

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us